medigraphic.com
ISSN 0016-3813 (Impreso)

2013, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2013; 149 (6)


Hiperaldosteronismo primario (HAP) por hiperplasia suprarrenal unilateral (HSU). Reporte de dos casos

Ferreira-Hermosillo A, Hernández-Martínez ÁF, Hernández-García I, Molina-Ayala M

Idioma: Español
Referencias bibliográficas: 23
Paginas: 668-672
Archivo PDF: 250.72 Kb.


RESUMEN

El HAP es considerado actualmente la principal causa de hipertensión arterial endocrina. Este síndrome está caracterizado por hipertensión, hipocalemia, actividad de renina plasmática (PRA) suprimida e incremento en la secreción de aldosterona. Las formas más comunes son la hiperplasia bilateral idiopática y el adenoma suprarrenal productor de aldosterona (enfermedad de Conn), y existen causas menos frecuentes como la HSU, el carcinoma suprarrenal o casos familiares de HAP. El porcentaje de pacientes con HSU como causa de HAP ha sido reportado hasta en el 2-3% de los casos; esta cifra está apoyada por lo observado por Kotsaftis, et al.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Young WF Jr. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology. 2003;144(6):2208-13.

  2. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006;2(4):198-208; quiz, 191 p following 230.

  3. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010;5:9.

  4. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD. Laboratory investigation of primary aldosteronism. Clin Biochem Rev. 2010;31(2):39-56.

  5. Enberg U, Volpe C, Hoog A, et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur J Endocrinol. 2004;151(1):73-85.

  6. Ferreira-Hermosillo A, Bernal-Garduño J, Hernández-García I, Molina- Ayala M. Debilidad muscular en un paciente con hipertensión arterial sistémica. Revista de Endocrinología y Nutrición. 2010;18(4):194-6.

  7. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266-81.

  8. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18.

  9. Cortes P, Fardella C, Oestreicher E, et al. [Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach]. Rev Med Chil. 2000;128(9):955-61.

  10. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85(5):1863-7.

  11. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90(1):72-8.

  12. Rossi GP, Ganzaroli C, Miotto D, et al. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens. 2006;24(2):371-9.

  13. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005;25 Suppl 1:S143-58.

  14. Kotsaftis P, Savopoulos C, Agapakis D, et al. Hypokalemia induced myopathy as first manifestation of primary hyperaldosteronism - an elderly patient with unilateral adrenal hyperplasia: a case report. Cases J. 2009;2:6813.

  15. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193-202.

  16. Chen SY, Shen SJ, Chou CW, Yang CY, Cheng HM. Primary aldosteronism caused by unilateral adrenal hyperplasia: rethinking the accuracy of imaging studies. J Chin Med Assoc. 2006;69(3):125-9.

  17. Katayama Y, Takata N, Tamura T, et al. A case of primary aldosteronism due to unilateral adrenal hyperplasia. Hypertens Res. 2005;28(4):379-84.

  18. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163-9.

  19. Karagiannis A, Tziomalos K, Kakafika A, Harsoulis F, Zamboulis C. Paralysis as first manifestation of primary aldosteronism. Nephrol Dial Transplant. 2004;19(9):2418-9.

  20. Huang YY, Hsu BR, Tsai JS. Paralytic myopathy--a leading clinical presentation for primary aldosteronism in Taiwan. J Clin Endocrinol Metab. 1996;81(11):4038-41.

  21. Goh BK, Tan YH, Chang KT, Eng PH, Yip SK, Cheng CW. Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases. World J Surg. 2007;31(1):72-9.

  22. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227-35.

  23. Doppman JL, Gill JR Jr. Hyperaldosteronism: sampling the adrenal veins. Radiology. 1996;198(2):309-12.




2020     |     www.medigraphic.com